Genotype–Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers

Abstract Cannabidiol (CBD) use has increased in America due to its widespread availability. Cannabidiol is metabolized by multiple polymorphic enzymes including CYP3A, CYP2C9, and CYP2C19. We sought to evaluate the genotype‐specific adverse events and pharmacokinetic profiles of cannabidiol, 7‐OH cannabidiol (an active metabolite), and 7‐COOH cannabidiol. We completed a secondary analysis of an open‐label, fixed‐sequence, single‐center study of cannabidiol in 33 healthy subjects. Patients first received a single dose of cannabidiol 5 mg/kg orally with serial plasma concentrations measured. Later,